YPrime Recognized as Trailblazer in Patient Engagement by Everest Group
24 sept. 2024 08h42 HE
|
Y-Prime, LLC
YPrime has been recognized as a Trailblazer in patient engagement by Everest Group for its innovative solutions that enhance clinical trial participation.
Noom Calls for Affordable Choices and Fair Pricing of Weight-Loss Medications Ahead of Tuesday’s Senate Testimony
24 sept. 2024 07h02 HE
|
Noom Inc
Noom issued a call for public support of a new petition demanding affordable choices and fair pricing for GLP-1 weight-loss medications.
KFSHRC Celebrates Landmark Contributions at 2024 NYC C3 Summit Davos of Healthcare
18 sept. 2024 06h00 HE
|
King Faisal Specialist Hospital & Research Centre
KFSHRC Celebrates Landmark Contributions at 2024 NYC C3 Summit Davos of Healthcare
KFSHRC at the forefront of precision medicine and genomic therapies in Saudi Arabia and the region
17 sept. 2024 08h48 HE
|
King Faisal Specialist Hospital & Research Centre
KFSHRC at the forefront of precision medicine and genomic therapies in Saudi Arabia and the region
KFSHRC Drives Saudi Arabia’s Rise as Global Biotech Powerhouse
17 sept. 2024 04h29 HE
|
King Faisal Specialist Hospital & Research Centre
KFSHRC Drives Saudi Arabia’s Rise as Global Biotech Powerhouse
KFSHRC Deputy CEO Receives Global Innovative Healthcare & Impact Transformation Award at New York Summit
16 sept. 2024 14h06 HE
|
King Faisal Specialist Hospital & Research Centre
KFSHRC Deputy CEO Receives Global Innovative Healthcare & Impact Transformation Award at New York Summit
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
15 sept. 2024 03h00 HE
|
23andMe, Inc.
23ME-01473 inhibited tumor growth in a patient-derived xenograft mouse model of non-small cell lung cancer Elevated levels of soluble and tumor-bound ULBP6 confirmed in squamous cell carcinomas and...
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
15 sept. 2024 03h00 HE
|
23andMe, Inc.
23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed partial response Higher tumor expression of CD200 and human...
One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
12 sept. 2024 16h05 HE
|
23andMe, Inc.
SUNNYVALE, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, in collaboration with lead researchers at...
Noom Introduces Industry-First $149 Compounded GLP-1 with a Taper-Off Guarantee, Offering a Sustainable Approach to Long-Term Weight Loss
12 sept. 2024 08h03 HE
|
Noom Inc
Noom will offer compounded GLP-1 injections paired with Noom’s powerful GLP-1 companion program, providing a sustainable pathway off the medications.